In celebration of Clinical Trials Day 2026, Pharmora have created a masterclass about medical monitoring. This is the first blog of the series, we look at the value of medical monitoring and the changing regulatory landscape.

More Than a Regulatory Checkbox

Clinical trials are complex, high-stakes endeavours. Behind every data point is a patient who has volunteered to help advance medicine. Protecting that patient – and capturing the data that will one day support a regulatory submission – requires vigilance, expertise, and the kind of systematic oversight that only medical monitoring can provide.

At Pharmora, medical monitoring sits at the heart of what we do. In this first blog in our series, we set out to explain what medical monitoring actually is, why it matters more than ever in today’s regulatory environment, and what real value it brings to those developing new medicines.

Defining Medical Monitoring

Medical monitoring is defined as the ongoing, systematic collection and evaluation of data regarding a trial participant’s safety over time with the purpose of detecting changes, identifying emerging risks, and ensuring the wellbeing of every individual enrolled in a clinical trial. It is not a single action or a document produced at the end of a study. It is a continuous, expert-led process that runs from the first participant enrolled to the last data point collected.

In practice, this means a qualified medical monitor – typically a physician or scientist with deep clinical and regulatory expertise – reviews patient data in real time, looks for patterns that may signal a safety concern, liaises with clinical sites, interprets adverse events in clinical context, and advises the sponsor on decisions that affect both participant safety and data integrity.

A Regulatory Landscape That is Changing

On 28th April 2026, updated guidelines under ICH E6(R3), incorporated into the UK Clinical Trials Regulations (CTR), formally came into force. This is a landmark moment for the industry.

One of the central principles of ICH E6(R3) is Quality by Design (QbD) – the requirement that quality is built into a clinical trial from the outset, rather than inspected at the end. For medical monitoring, this is significant. Under QbD, sponsors must prospectively identify the critical data and processes that matter most for participant safety and the reliability of trial results, and put in place robust, risk-proportionate oversight to protect them.

In short, thoughtful, proactive medical monitoring is no longer simply best practice, it is becoming a regulatory expectation. Sponsors who engage medical monitoring expertise early, and embed it within their trial design, will be better positioned to demonstrate compliance, protect their data, and ultimately bring medicines to patients more efficiently.

The Value Medical Monitoring Brings

The benefits of high-quality medical monitoring extend far beyond regulatory compliance. For sponsors, whether biotechs bringing a first-in-class asset forward, or established companies developing biosimilars, medical monitoring delivers value across the entire trial lifecycle:

• Early identification of safety signals, enabling timely decisions that protect participants and preserve trial integrity;
• Reduced risk of data queries and regulatory questions at submission, saving time and cost downstream;
• Informed decision-making at critical trial milestones, supported by expert clinical interpretation rather than data alone;
• Confidence for investors and partners that the programme is being run to the highest standards.

The Skills Behind the Science

Medical monitors are not simply data reviewers. The best in the field bring together clinical medicine, pharmacology, regulatory knowledge, and an ability to exercise sound judgement under uncertainty. They understand that a single unexpected laboratory value may be clinically irrelevant, or it may be the first sign of a serious problem. That distinction requires an appreciation of nuance gained from years of experience, which cannot be replicated by automated systems alone.

At Pharmora, our medical monitors are physicians and scientists with hands-on experience across a broad range of therapeutic areas and trial phases. We invest heavily in training and development, and our CMO – a Fellow of the Faculty of Pharmaceutical Medicine – provides clinical leadership across all our projects. This depth of expertise is what we bring to every engagement.

What’s Next in This Series

Over the next four blogs, we will explore what medical monitoring means for specific audiences: biotechs building their first trial, investors assessing the strength of a clinical asset, and developers working in the biosimilars and generics space. Each group faces different challenges, where medical monitoring has a specific, tangible role to play.

We hope this series helps to raise awareness of the value that expert medical monitoring brings to drug development and encourages those planning clinical programmes to engage this expertise early, when it can make the most difference.

If you are looking to read the rest of this exciting masterclass, click the links below to navigate through the series:
2 – Medical Monitoring for Biotechs
3 – Medical Monitoring and the Investor Perspective
4 – Medical Monitoring in Biosimilar Development
5 –  Medical Monitoring in Generics Development

To find out how Pharmora can support your programme, contact us at info@pharmora.com or visit www.pharmora.com.